Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Market outline PART 05: Pipeline landscape PART 06: Market landscape • Market overview • Five forces analysis PART 07: Market segmentation by ROA • Oral • Topical PART 08: Market segmentation by disease type • Interdigital tinea pedis • Vesicular tinea pedis PART 09: Geographical segmentation • Tinea pedis treatment market in Americas • Tinea pedis treatment market in EMEA • Tinea pedis treatment market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Increased funding for antifungal research • Increased focus on combination therapies • Advent of novel therapies PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • GSK • Valeant • Exeltis USA • Viamet Pharmaceuticals • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Symptoms of tinea pedis Exhibit 02: Pipeline analysis Exhibit 03: Global tinea pedis treatment market: Snapshot Exhibit 04: Global tinea pedis treatment market 2016-2021 ($ millions) Exhibit 05: Opportunity analysis: Global tinea pedis treatment market Exhibit 06: Five forces analysis Exhibit 07: Global tinea pedis treatment market by ROA 2016 Exhibit 08: Global tinea pedis treatment market by disease type 2016 Exhibit 09: Global interdigital tinea pedis treatment market 2016-2021 ($ millions) Exhibit 10: Global vesicular tinea pedis treatment market 2016-2021 ($ millions) Exhibit 11: Global tinea pedis treatment market by geography 2016 and 2021 Exhibit 12: Global tinea pedis treatment market by geography 2016-2021 ($ millions) Exhibit 13: Market scenario in Americas Exhibit 14: Tinea pedis treatment market in Americas 2016-2021 ($ millions) Exhibit 15: Market scenario in EMEA Exhibit 16: Tinea pedis treatment market in EMEA 2016-2021 ($ millions) Exhibit 17: Market scenario of APAC Exhibit 18: Tinea pedis treatment market in APAC 2016-2021 ($ millions) Exhibit 19: Competitive structure analysis of global tinea pedis treatment market 2016 Exhibit 20: Strategic success factors of companies in global tinea pedis treatment market Exhibit 21: GSK: Strength assessment Exhibit 22: GSK: Strategy assessment Exhibit 23: GSK: Opportunity assessment Exhibit 24: Valeant: Key highlights Exhibit 25: Valeant: Strength assessment Exhibit 26: Valeant: Strategy assessment Exhibit 27: Valeant: Opportunity assessment Exhibit 28: Exeltis USA: Strength assessment Exhibit 29: Exeltis USA: Strategy assessment Exhibit 30: Exeltis USA: Opportunity assessment Exhibit 31: Viamet Pharmaceuticals: Strength assessment Exhibit 32: Viamet Pharmaceuticals: Strategy assessment Exhibit 33: Viamet Pharmaceuticals: Opportunity assessment

GSK, Exeltis USA, Valeant, Viamet Pharmaceuticals, Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio , NovaBiotics, Novan , Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, and Tinea Pharmaceuticals.